Fierce Biotech

1. Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma

   Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma arlene.weintraub Wed, 01/20/2021 - 09:32

2. GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

   GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer badams Wed, 01/20/2021 - 09:28

3. Ride Health gives patients a lift to COVID-19 treatment, vaccine trials

   Ride Health gives patients a lift to COVID-19 treatment, vaccine trials chale Wed, 01/20/2021 - 09:16

4. Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits

   Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits badams Wed, 01/20/2021 - 09:03

5. Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

   Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer ntaylor Wed, 01/20/2021 - 08:52